home / stock / entbf / entbf news

ENTBF News and Press, Entheon Biomedical Corp Com From 03/30/21

Stock Information
Company Name: Entheon Biomedical Corp Com
Stock Symbol: ENTBF
Market: OTC
Website: entheonbiomedical.com
Menu
ENTBF ENTBF Quote ENTBF Short ENTBF News ENTBF Articles ENTBF Message Board
Get ENTBF Alerts

News, Short Squeeze, Breakout and More Instantly...
ENTBF - March Psychedelic Capital Investigates Ethical IP and Financial Instruments

Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund , the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic ...
ENTBF - Ellis Martin Report: Entheon Biomedical's (ENTBF) HaluGen Psychedelics Genetic Test Ahead of Ethical Clinical DMT Therapy

Malibu, CA, United States (ABN Newswire) - Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (OTCMKTS:ENTBF). Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the...

ENTBF - Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs

Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon's Advisory Board Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) - &#x...

ENTBF - Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

Completion of research and development phase for HaluGen's Psychedelics Genetic Test Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psych...
ENTBF - Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study

Vancouver, British Columbia--(Newsfile Corp. - February 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming pre-...

ENTBF - Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development

Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointmen...

ENTBF - Ellis Martin Report: Entheon Biomedical (ENBTF) CEO Timothy Ko on the Ethical Clinical Use of DMT for Treating Substance Abuse, Depression, Anxiety and More

Malibu, CA, United States (ABN Newswire) - Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (OTCMKTS:ENTBF). Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of...
ENTBF - Entheon Biomedical Hires ClearTV Executive as VP of Digital Experience Entertainment Veteran Jonna Birgans to Oversee Digital and VR Content Development

Vancouver, British Columbia--(Newsfile Corp. - February 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment...

ENTBF - Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments

Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) -  Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company" ), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides an update on licen...

ENTBF - KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021

KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021 Featuring presentations by eminent psychedelics companies and industry leaders including keynote speakers, Rick Doblin, MAPS and Amy Emerson, MAPS Public Benefit Corporat...
Previous 10 Next 10